National Psoriasis Foundation
12
0
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
Role: collaborator
Smart Phone Delivered Cognitive Behavioral Therapy for Adults With Psoriasis and Co-Morbid Depression Symptoms
Role: collaborator
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
Role: collaborator
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
Role: collaborator
Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris
Role: collaborator
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
Role: collaborator
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Role: collaborator
Light Treatment Effectiveness (LITE) Study
Role: collaborator
Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
Role: collaborator
Genetic Analysis of Pediatric Psoriasis
Role: collaborator
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
Role: collaborator
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study
Role: collaborator
All 12 trials loaded